Cyclin-dependent kinase like-5 (CDKL5) disorder is a rare neurodevelopmental disease caused by mutations in the CDKL5 gene. The consequent misexpression of the CDKL5 protein in the nervous system leads to a severe phenotype characterized by intellectual disability, motor impairment, visual deficits and early-onset epilepsy. No therapy is available for CDKL5 disorder. It has been reported that a protein transduction domain (TAT) is able to deliver macromolecules into cells and even into the brain when fused to a given protein. We demonstrate that TAT-CDKL5 fusion protein is efficiently internalized by target cells and retains CDKL5 activity. Intracerebroventricular infusion of TAT-CDKL5 restored hippocampal development, hippocampus-dependent memory and breathing pattern in Cdkl5-null mice. Notably, systemically administered TAT-CDKL5 protein passed the blood-brain-barrier, reached the CNS, and rescued various neuroanatomical and behavioral defects, including breathing pattern and visual responses. Our results suggest that CDKL5 protein therapy may be an effective clinical tool for the treatment of CDKL5 disorder. †
Introduction
Cyclin-dependent kinase-like 5 (CDKL5) disorder is a severe X-linked neurodevelopmental disease caused by mutations in the CDKL5 gene, which lead to a lack of CDKL5 protein expression or function. The CDKL5-related encephalopathy affects mostly girls and, due to the numerous clinical features that overlap with the better-characterized Rett syndrome (RTT), it was initially termed as an 'early seizure variant' or 'Hanefeld variant' of RTT. Similarities between RTT and CDKL5 encephalopathy are related to the severe neurodevelopmental impairment, intellectual disability, motor impairment and in some cases respiratory dysregulation. However, a systematic analysis of clinical symptoms across patients has led to the conclusion that CDKL5 disorder is a distinct clinical entity characterized by early-onset epileptic seizures (in the first few months of life), hypotonia, abnormal eye tracking and severe visual impairment (1) (2) (3) (4) .
CDKL5 is highly expressed in the brain, mainly in neurons with both a nuclear and dendritic localization (5) (6) (7) (8) . In the early postnatal period, CDKL5 brain expression exhibits a peak (6, 8) , suggesting its potential importance in brain maturation. Animal models of CDKL5 disorder, Cdkl5 knockout (KO) mice (9) (10) (11) , have recently been created to clarify the role of CDKL5 in brain development and in the etiology of CDKL5 disorder. Cdkl5 KO mice recapitulate different features of CDKL5 disorder, exhibiting severe impairment in hippocampus-dependent learning and memory, visual and respiratory deficits, and motor stereotypies (9, 10, 12, 13) . These defects are associated with neuroanatomical alterations, such as reduced dendritic arborization of hippocampal and cortical neurons, reduced dendritic spine density and altered connectivity (10, (12) (13) (14) (15) (16) .
The failure of proteins to penetrate the cell membrane prevents their use as a therapeutic tool in a variety of monogenic disorders caused by the lack of function of a single protein. Recently, protein transduction domains (PTDs) have been shown to promote the delivery of proteins into living cells and through the blood brain barrier. PTDs are small peptides that are able to ferry much larger molecules into cells independently, by classical endocytosis (17) . The HIV-1 transactivator of transcription (TAT) protein is the best characterized viral PTD-containing protein. Earlier experiments with the TAT-PTD protein domain demonstrated successful transduction of fusion proteins up to 120 kDa into murine cells (18) (19) (20) . Schwarze et al. (19) reported that a recombinant TAT-b-galactosidase protein, injected intraperitoneally into mice, was distributed to all tissues, including the brain, and retained its biological activity. Importantly, the TAT-PTD has not been reported to have any toxic effects or immunogenicity problems so far (17) .
Although pharmacological treatments are used to control seizures, no cure or effective treatments are currently available to ameliorate cognitive and behavioral symptoms for CDKL5 disorder. The aim of this study was to develop a protein substitution therapy for CDKL5 disorder in order to compensate for the lack of function of the CDKL5 protein. We produced a TAT-CDKL5 protein that was efficiently transduced into cells, and subsequently evaluated whether central and peripheral administration of this fusion protein improves brain development and behavior in a mouse model of CDKL5 disorder.
Results

Target cells are efficiently transduced by TATj-CDKL5 fusion protein
Alternative splice isoforms for the human CDKL5 gene have been described (21, 22) . The original CDKL5 transcript generates a protein of 1030 amino acids [CDKL5 5 (22) , 115 kDa]. While CDKL5 5 is the first characterized CDKL5 isoform, a recently identified transcript, characterized by an altered C-terminal region, is likely to be relevant for CDKL5 brain functions [CDKL5 1 (22) , 107 kDa] (23) . No knowledge as to a different activity of the CDKL5 isoforms is currently available. To identify which CDKL5 isoform was more suitable for a protein therapy, we produced both TATj-CDKL5 1 and TATj-CDKL5 5 fusion proteins and compared their production and activity. Since full-length CDKL5 protein cannot be produced in bacteria (24) , we induced the expression of the TATj-CDKL5 recombinant protein in mammalian cells. In order to enhance protein recovery, we took advantage of a synthetic TATj-PTD in which mutation of the furin recognition sequences, but retention of protein transduction activity, allows secretion of recombinant proteins (25) . Due to the absence of a suitable anti-CDKL5 antibody that works on brain tissue, the TATj-CDKL5 fusion proteins were tagged with a GFP protein to monitor their expression levels.
Western blot analysis detected high levels of TATj-GFP-CDKL5 1 (Fig. 1A) and TATj-GFP-CDKL5 5 (Supplementary Material, Fig. S2A ) proteins in the culture medium 48 h after transfection of HEK293T cells, indicating that both TATj-GFP-CDKL5 proteins were efficiently secreted from these cells. However, the recovery of TATj-GFP-CDKL5 1 fusion protein from the culture medium was higher than that of TATj-GFP-CDKL5 5 (Supplementary Material, Fig. S2A ), suggesting a more efficient secretion of the shorter CDKL5 isoform (CDKL5 1 ).
To investigate whether target cells were transduced with the secreted TATj-GFP-CDKL5 proteins, hippocampal neurons were incubated with the purified TATj-GFP-CDKL5 1 protein. After 1 h of incubation, cells were lysed and total protein extracts were immunoblotted for TATj-GFP-CDKL5 1 protein quantification. As shown in Figure 1B and C, TATj-GFP-CDKL5 1 is efficiently internalized by target cells. The internalization in target cells was confirmed by confocal microscopy (Fig. 1D ). Figure 1D shows serial confocal images of TATj-GFP-CDKL5 1-transduced hippocampal neurons, demonstrating that TATj-GFP-CDKL5 1 protein is internalized by target cells and localized mainly in the cytoplasm, consistent with CDKL5 cellular distribution (7) . Similar results for transduction efficiency were obtained with the TATj-GFP-CDKL5 5 The efficacy of protein therapeutics are limited by pharmaceutical issues among which the most important is the protein half-life. We found that, when transduced into cells, the TATj-GFP-CDKL5 1 half-life was about 12 h (Supplementary Material, Fig. S2D ), suggesting an intracellular stability of the fusion protein that is appropriate for in vivo treatments.
TATj-CDKL5 fusion protein retains wild-type activity
Since CDKL5 is known to inhibit proliferation of neuroblastoma cells (26) , we evaluated TATj-GFP-CDKL5 fusion protein activity by treating SH-SY5Y neuroblastoma cells with purified TATj-GFP-CDKL5 1 , TATj-GFP-CDKL5 5 or TATj-GFP protein as controls ( Fig. 2A-C, Supplementary Material, Fig. S2C ). The increase of CDKL5 protein levels within neuroblastoma cells, through TATj-GFP-CDKL5 1 protein treatment (Fig. 2C) , caused a strong inhibition of cell proliferation (evaluated as a mitotic index, Fig. 2A and B) compared to control treatment (TATj-GFP). We found that TATj-GFP-CDKL5 5 isoform has the same antiproliferative activity as TATj-GFP-CDKL5 1 isoform on neuroblastoma cells ( Fig. 2A and B; Supplementary Material, Fig. S2C ), suggesting a similar physiological activity. Considering that the addition of GFP may alter the activity of CDKL5, we compared the activity of the TATj-GFP-CDKL5 5 fusion protein with a TATj-CDKL5 5 protein without GFP and with only a small 3xFLAG-tag at the C-terminus (Supplementary Material, Figs S1 and S2C). We found a similar effect on SH-SY5Y neuroblastoma cells in terms of inhibition of proliferation, indicating that the GFP-tag does not affect CDKL5 activity (Supplementary Material, Fig. S2C ). Treatment with the kinase-dead form of CDKL5 [TATj-GFP-CDKL5(K42R) 1 , Fig. 2B ] did not affect SH-SY5Y cell proliferation, indicating that the TATj-GFP-CDKL5 fusion proteins had preserved the kinase activity.
It has been shown that in neurons CDKL5 has mainly a cytoplasmic localization with an enrichment at the level of dendritic spines (6) . To assess whether the transduced TATj-GFP-CDKL5 localizes as the native form, we treated hippocampal neuronal cultures from Cdkl5 KO male (À/Y) mice with purified TATj-GFP-CDKL5 1 , or TATj-GFP (added to the culture medium). While transduced TATj-GFP-CDKL5 1 located mainly at the nuclear level in astrocytes (Supplementary Material, Fig. S3A ), we found that in hippocampal neurons internalized TATj-GFP-CDKL5 1 was distributed in the cytoplasmic compartment and, at a dendritic level, it was distributed in a manner that suggested a spine localization (Fig. 1D,  Supplementary Material, Fig. S3B ). Confocal images showed TATj-GFP-CDKL5 1 co-localization with the postsynaptic density protein PSD-95 (Fig. 2E ) and with the presynaptic protein synaptophysin (SYN; Fig. 2E ), suggesting that the exogenous protein localizes at the same postsynaptic level (i.e. dendritic spines) as the native CDKL5. Similar results were obtained with TATj-GFP-CDKL5 5 (data not shown). In contrast, the control GFP protein (TATj-GFP) showed a widespread distribution along the dendrites (Fig. 1D,  Supplementary Material, Fig. S4A ).
In order to confirm the wild-type activity of the recombinant proteins, hippocampal neuronal cultures from Cdkl5 À/Y mice were grown in the presence of TATj-GFP-CDKL5 1 or TATj-GFP. from Cdkl5 À/Y mice treated for 1 h with purified TATj-GFP-CDKL51 protein (50 ng). Cells were co-stained for CDKL5 (red) and GFP (green) expression and nuclei were counterstained with TO-PRO-3 far red dye. Scale bar ¼ 10 mm. (D) Series of four images (1-4) from confocal microscopy (Z stack size 1 mm) of the same hippocampal neuron as in C.
Images confirm that TATj-GFP-CDKL5 1 protein is internalized by target cells. Scale bar ¼ 10 mm. immunostaining with an anti-GFP antibody (red) and an anti-b III tubulin antibody (TUBJ, green). Nuclei were counterstained with Hoechst. Higher magnification shows the enlargement of a dendrite segment included in the dotted box. Scale bar ¼ 25 mm (lower magnification) ¼ 5 mm (higher magnification). (E): Confocal microscopy images of a dendrite segment of a hippocampal neuron treated with TATj-GFP-CDKL5 1 as in (D). Images show co-localization of TATj-GFP-CDKL5 1 protein with a pre-synaptic protein (synaptophysin, SYN; left panels) and a post-synaptic protein (PSD-95; right panels). TATj-GFP-CDKL5 1 immunodetection was conducted using an anti-GFP antibody. Scale bar ¼ 5mm. (F-H) Hippocampal neuronal cultures from Cdkl5 À/Y mice were treated, starting from the second day in culture, every two days for 8 days, with TATj-GFP-CDKL5 1 or TATj-GFP-CDKL5(K42R) 1 proteins (50 ng) and the effects on neurite outgrowth, synaptic innervations, and spine density were assessed. The histo- Confirming previous evidence (14) , the absence of Cdkl5 caused a reduction in neuronal maturation, as shown by the reduced dendritic length ( Fig. 2F and I; Supplementary Material, Fig. S4B ), number of synaptic terminals (SYN; Fig. 2G and I) and spine density ( Fig. 2H and I ; Supplementary Material, Fig. S4C ) (14) . Treatment with TATj-GFP-CDKL5 1 restored these defects ( Fig. 2D-I ; Supplementary Material, Fig. S4B and C) , confirming that the CDKL5 fusion protein retains physiological activity. Fig. S5C ). Subcellular localization of transduced protein showed TATj-GFP-CDKL5 1 co-localization with the postsynaptic density protein PSD-95, indicating a spine localization. Cdkl5 KO (À/Y) mice received a single daily injection for five consecutive days, followed by a two-day rest period and then five additional days of a single injection, for a total of 10 injections (Fig. 3A) . At the end of the treatment, animals were behaviorally tested during a 10-day period and sacrificed after testing ( Table S1 ) were observed in treated Cdkl5 À/Y mice, indicating that TATj-GFP-CDKL5 1 treatment does not affect these aspects of animal health. Moreover, treatment did not cause activation of microglial cells, evaluated using allograft inflammatory factor 1 (AIF-1) staining (Supplementary Material, Fig. S6B and C), indicating an absence of inflammatory response to continuous TATj-GFP-CDKL5 1 treatment.
First, we evaluated behavioral improvement due to TATj-GFP-CDKL5 1 treatment by focusing on the hippocampus, which is known to be severely impaired in Cdkl5 À/Y mice at a functional level (10, 13, 27) . To this aim, we used the Morris water maze (MWM) and passive avoidance (PA) tests. Cdkl5 KO mice exhibit severe deficits for both these tasks (13, 14) . In the MWM test, no learning improvement was detected in TATj-GFPtreated Cdkl5 À/Y mice compared to their untreated counterparts (Fig. 3B) , indicating no effect of the control protein.
Importantly, TATj-GFP-CDKL5 1 -treated Cdkl5 À/Y mice underwent an improvement in their learning ability starting from day 3 and reaching a performance similar to that of control (þ/Y) mice on day 5 (Fig. 3B ). In the probe trial, the latency to find the hidden platform was severely impaired in untreated and TATj-GFP-treated Cdkl5 À/Y mice (Fig. 3C) . TATj-GFP-CDKL5 1 -treated Cdkl5 À/Y mice showed a statistically significant improvement in memory performance (Fig. 3C) . In the PA test, all groups showed similar step-through latencies on the first day (Fig. 3D) . After 24 h, untreated and TATj-GFP-treated Cdkl5 À/Y mice were severely impaired in performing this task, as demonstrated by a reduced latency to enter the dark compartment in comparison with control (þ/Y) mice. In contrast, TATj-GFP-CDKL5 1 -treated Cdkl5 À/Y mice showed a similar latency as untreated þ/Y mice, indicating memory restoration (Fig. 3D) .
Using whole-body plethysmography (WBP), we recently found that sleep apneas occur more frequently in Cdkl5 À/Y than in control (þ/Y) mice (28) (Fig. 3F) , indicating a breathing disturbance during sleep in Cdkl5 À/Y mice. Though the sleep apnea occurrence rate of TATj-GFP-treated Cdkl5 À/Y mice resulted to be slightly lower compared to untreated Cdkl5 À/Y mice, probably due to a minor stress response resulting from habituation to the prolonged handling (29) , treatment with TATj-GFP-CDKL5 1 led to a drastic reduction in the number of apneas that became similar to that of control mice (þ/Y) ( Fig. 3E and F) .
Finally, in order to examine the effect of TATj-GFP-CDKL5 1 on motor stereotypies, mice were tested for hind-limb clasping before and after the 10 days of treatment (Fig. 3G) . While þ/Y mice exhibited no hind-limb clasping, Cdkl5 À/Y mice spent about 1/4 of the test session in the clasping position (Fig. 3G) . A similar clasping duration was observed in Cdkl5 À/Y mice after treatment with TATj-GFP (Fig. 3G ). In contrast, Cdkl5 À/Y mice treated with TATj-GFP-CDKL5 1 showed a significant decrease in clasping ( Fig. 3G) , indicating a treatment-induced improvement of motor stereotypies.
These data show that CDKL5 replacement positively impacts on numerous behavioral deficits due to loss of Cdkl5 expression.
Intracerebroventricular treatment with TATj-CDKL5 protein restores dendritic abnormalities in Cdkl5 KO mice
In order to establish whether the improvement of behavioral performance is due to a recovery of the brain structural defects that characterize Cdkl5 KO mice (10,12,13,27), we analyzed dendritic morphology and connectivity in the hippocampus of Cdkl5 À/Y mice that were treated according to the schedule shown in Figure 3A and sacrificed 10 days after the last intracerebroventricular injection.
The hippocampal dentate gyrus (DG) exhibits ongoing neurogenesis throughout life. The new granule neurons express doublecortin (DCX) from 1 to 4 weeks after neuron birth (30) . We took advantage of this feature to examine the effect of treatment on neurons born shortly before, during the treatment, and in the 10-day period followed the beginning of treatment. As previously reported (12), DCX-positive granule cells of Cdkl5 À/Y mice exhibit a shorter dendritic length in comparison with their wild-type (þ/Y) counterparts ( Fig. 4A and B). Treatment with TATj-GFP-CDKL5 1 increased total dendritic length in Cdkl5 À/Y mice to levels similar to those of wild-type mice ( Fig. 4A and B) . Treatment with TATj-GFP had no effect on dendritic length ( Fig. 4A and B ). These data, taken together, show that replacement of CDKL5 is able to restore dendritic development.
Previous evidence showed that neurons of Cdkl5 KO mice are characterized by severe dendritic pathology in terms of dendritic architecture and spine density (13) . In order to establish whether treatment is able to reshape the dendritic pattern of neurons born well before treatment, in Golgi-stained brain sections ( Fig. 4C) we examined the dendritic tree of granule cells of the DG and pyramidal neurons of hippocampal field CA1. Granule neurons of Cdkl5 À/Y mice displayed reduced dendritic length ( Fig. 4D and E) in comparison with wild-type (þ/Y) mice, due to a reduction of the number of branches (Fig. 4G) , with no differences in the mean branch length (Fig. 4F) . While dendritic length and number of branches were completely rescued by treatment with TATj-GFP-CDKL5 1 , treatment with TATj-GFP had no effect (Fig. 4D , E and G). Similarly to granule neurons, pyramidal neurons of field CA1 (Fig. 4H ) exhibited dendritic hypotrophy at the level of both the apical and basal dendritic trees (Fig. 4I ). While treatment with TATj-GFP did not affect the dendritic arbors of pyramidal neurons, treatment with TATj-GFP-CDKL5 1 restored total dendritic length (Fig. 4I) . These results show that CDKL5 replacement can restore the dendritic length of mature neurons and of neuronal populations in different hippocampal regions.
Evaluation of dendritic spine density showed that both the granule cells of the DG and CA1 pyramidal neurons had a reduced spine density in untreated Cdkl5 À/Y mice in comparison with wild-type (þ/Y) mice ( Fig. 5A-D) . Cdkl5 À/Y mice treated with TATj-GFP-CDKL5 1 underwent restoration of spine density in both neuron types ( Fig. 5A-D) . Dendritic spines are heterogeneous in size and shape, and can be classified as: immature spines (filopodia, thin-shaped and stubby-shaped) and mature spines (mushroom and cup shapes) (see Fig. 5E and F) , which is consistent with the recovery of the mature spine number (Fig. 5C ).
These results indicate that CDKL5 replacement restores the hippocampal structural defects that characterize Cdkl5 KO mice with an effect that extends beyond the cessation of treatment.
Systemically injected TATj-CDKL5 protein reaches the mouse brain
In a second set of experiments, we sought to establish whether systemically injected TATj-GFP-CDKL5 protein crosses the blood-brain barrier. This is an essential step for development of a CDKL5 protein substitution protocol suitable for clinical application. Since the blood-brain barrier increases its selectivity with age, we evaluated whether TATj-GFP-CDKL5 protein crosses the blood-brain barrier in newborn and adult mice ( Fig. 6A-D; Supplementary Material, Fig. S7A and B) . Seven-day old pups were subcutaneously injected with TATj-GFP-CDKL5 1 , TATj-GFP-CDKL5 5 , TATj-GFP or vehicle (negative control) and sacrificed 4 h after the injection ( Fig. 6A and B ; Supplementary Material, Fig. S7A ). The localization of the TATj-GFP-CDKL5 1 , TATj-GFP-CDKL5 5 and TATj-GFP proteins in the brain was evaluated by immunohistochemistry, using an anti-GFP antibody. We found the presence of the TATj-GFP-CDKL5 and TATj-GFP proteins in the brain of mouse pups 4 h after the protein injection ( Fig. 6B; Supplementary Material, Fig. S7A ). To assess whether the TATj-GFP-CDKL5 protein crosses the highly selective permeability barrier of the adult brain, P90 mice were intravenously injected (a procedure that is feasible in adult mice) with TATj-GFP-CDKL5 and sacrificed 1 h later ( Fig. 6C and D;  Supplementary Material, Fig. S7B ). As shown in Figure 6D , the TATj-GFP-CDKL5 1 protein was distributed in the brain. These data demonstrate that TATj-GFP-CDKL5 protein is effectively transported across both the 'immature' and 'mature' blood-brain barrier.
Effect of systemically administered TATj-CDKL5 protein on dendritic morphology and behavior
We used an infusion method which is based on a programmable pump (IPRECIO, Primetech, Japan) implanted under the skin with a refillable reservoir. The pump was connected to a catheter implanted in the carotid artery. In view of the turnover of the TATj-GFP-CDKL5 1 (see preceding sections), we decided to use a twice-a-day infusion protocol (bolus delivered at 9 am and 9 pm; see Materials and Methods for details) for the duration of 10 days (Fig. 7A ). Mice were behaviorally tested from day 8 to day 12 and a separate cohort of animals were sacrificed on day 10 for histological analysis. Similarly to ICV treatment, no changes in terms of body weight (Supplementary Material, Table S1 ) were observed in Cdkl5 À/Y mice that had undergone systemic administration of TATj-GFP-CDKL5 1 .
In order to establish whether systemic administration of TATj-GFP-CDKL5 1 had positive effects on the dendritic hypotrophy of hippocampal neurons, we examined both newborn and mature granule cells. We found that, unlike TATj-GFP-treated Cdkl5 À/Y mice, Cdkl5 À/Y mice treated with the TATj-GFP-CDKL5 1 underwent restoration of total dendritic length of DCX-positive neurons (newborn granule cells) (Fig. 7B and C) as well as Golgi-stained granule cells (mature neurons) (Fig. 7D) . Moreover, Cdkl5 À/Y mice treated with TATj-GFP-CDKL5 1 underwent restoration of granule cell spine density (Fig. 7E) .
Since we could not examine the effect of treatment on learning and memory with the MWM test because this test requires a motility in the water that would have been hampered by the weight and size of the implanted pump, learning and memory was evaluated using the Barnes maze. We found that, while untreated and TATj-GFP-treated Cdkl5 À/Y mice took longer to locate the target hole compared to control mice, TATj-GFP-CDKL5 1 -treated Cdkl5 À/Y mice underwent an improvement in their learning ability (Fig. 7F ). In the probe trial, the latency to find the target hole was severely impaired in untreated and TATj-GFP-treated Cdkl5 À/Y mice (Fig. 7F) . TATj-GFP-CDKL5-treated Cdkl5 À/Y mice showed a similar improvement in latency to find the hole (Fig. 7F) , indicating an effect of the protein therapy on memory performance.
We further examined digging and nesting, two spontaneous home-cage social behaviors that are associated with autisticlike phenotypes (32) (33) (34) . In both tests, untreated as well as TATj-GFP-treated Cdkl5 À/Y mice exhibited an impaired performance compared with control (þ/Y) mice. They showed reduced digging episodes and poorer or no nest-building compared with control (þ/Y) mice ( Fig. 7G and H) . Digging and nesting behaviors were corrected by the TATj-GFP-CDKL5 1 protein treatment ( Fig. 7G and H) , indicating a positive effect of the treatment on these spontaneous social behaviors.
Cdkl5 À/Y mice showed elevated locomotor activity and stereotyped behavior [repetitive vertical jumping (35) ] in an open field compared with wild-type littermate controls ( Fig. 7I and J) . Cdkl5 À/Y mice moved at a higher average velocity (Fig. 7I) , traveled a significantly longer distance (Fig. 7I) and showed an increased number of vertical stereotyped jumps (Fig. 7J) . A similar elevated locomotor activity and stereotyped behavior was observed in Cdkl5 À/Y mice after treatment with TATj-GFP ( Fig. 7I and J) . In contrast, Cdkl5 À/Y mice treated with TATj-GFP-CDKL5 1 showed a significant decrease in hyperactivity (Fig. 7I ) and motor stereotypies (Fig. 7J) , indicating a treatment-induced improvement of autistic-like behaviors.
Effect of systemically administered TATj-CDKL5 protein on breathing pattern and cortical visual responses
Since impaired breathing pattern, particularly during sleep, and visual responses represent promising biomarkers for preclinical and clinical studies on CDKL5 disorder (28, 36) , we evaluated the effect of the treatment with TATj-GFP-CDKL5 1 or TATj-GFP proteins on these two patterns in Cdkl5 KO mice. In order to assess the long-lasting effect of the treatment, Cdkl5 À/Y mice were tested on the 10th day of treatment and after 5 and 10 days after the end of treatment (Fig. 8A) .
We found that, unlike TATj-GFP treatment, 10 days of treatment with TATj-GFP-CDKL5 1 led to a significant reduction in the occurrence rate of REM sleep apneas in Cdkl5 À/Y mice ( Fig. 8B) . The positive effect of the TATj-GFP-CDKL5 1 treatment on sleep apneas gradually disappeared 5-10 days after treatment cessation (Fig. 8B) . Cortical visual responses were assessed using non-invasive transcranial intrinsic optical signal (IOS) imaging, a method that allows us to monitor the visually evoked responses in the same animal at different time points (36) . We found that, while TATj-GFP-treated Cdkl5 À/Y mice showed no improvement in visual responses compared with the baseline condition ( Fig. 8C and D) , Cdkl5 À/Y mice treated with the TATj-GFP-CDKL5 1 protein underwent a progressive restoration of visual responses that fell within the 95% confidence interval of wild-type mice (Fig. 8C  and D) . The positive effect of the TATj-GFP-CDKL5 1 protein treatment on visual response was retained 5-10 days after treatment cessation (washout), indicating a long-lasting effect of the protein replacement treatment.
In order to establish whether the improvement of visual performance of treated Cdkl5 À/Y mice is associated with recovery of the defective synaptic organization that characterizes the primary visual cortex (V1) of Cdkl5 À/Y mice (16), we analyzed spine density of layer II/III pyramidal neurons (Fig. 8E, Supplementary Material,  Fig. S8B ). While untreated and TATj-GFP-treated Cdkl5 À/Y mice showed a lower spine density compared with control (þ/Y) mice (Fig. 8E ), mice treated with TATj-GFP-CDKL5 1 underwent an increase in spine density (Fig. 8E ). This effect was present at the end of treatment (short-term effect) and, albeit to a lesser extent, 10 days after treatment cessation (long-term effect). Evaluation of the number of PSD-95 immunoreactive puncta showed that, consistent with previous evidence (16) , Cdkl5 À/Y mice displayed a strong reduction in the number of PSD-95-positive puncta in layers II/III of V1 compared with control (þ/Y) mice (Fig. 8F) . Treatment with TATj-GFP-CDKL5 1 restored the number of PSD-95-positive puncta at treatment cessation (short term, Fig. 8F ) and this effect was retained 10 days after treatment cessation (long term, Fig. 8F ), which is consistent with the effect of treatment on spine density (Fig. 8E) .
Discussion
No therapies are presently available for the improvement of the neurological phenotypes associated with CDKL5 disorder. Since mutations in the CDKL5 gene lead to a lack of functional CDKL5, delivery of a functional CDKL5 protein to the brain may represent a therapeutic approach of choice. Our study provides novel evidence that a protein substitution therapy, aimed at compensating for the lack of CDKL5 function, is feasible and effective. To deliver an active CDKL5 protein into the brain and within brain cells, we constructed the TATj-CDKL5 fusion protein using the HIV PTD TAT as a delivering moiety. We demonstrated that TATj-CDKL5 fusion protein is internalized by cells and retains CDKL5 activity. When injected in vivo, TATj-CDKL5 fusion protein was able to cross the blood-brain barrier and diffuse into brain cells. Cdkl5KO mice treated with TATj-CDKL5 protein underwent a neurodevelopmental and behavioral improvement or even rescue. These promising results suggest that a protein substitution therapy with a TATj-CDKL5 fusion protein may be a successful therapy for CDKL5 disorder. Moreover, our data represent the first successful attempt to use systemic protein replacement therapy for a neurodevelopmental disorder.
It is possible to create a functional TATj-CDKL5 fusion protein
The results of initial studies in the field of protein therapy technology led to anticipation that it would soon be possible to develop fusion proteins for different brain diseases. However, it turned out that expression and purification of fusion proteins have methodological limitations. For instance, unsuccessful cell transduction has been described for a number of fusion constructs, including linking the TAT-PTD with diphtheria toxin A (37), with Leishmania gp63 (38) or with aromatic carboxylic acid (39) . In the present study, we succeeded in producing a functional TATj-CDKL5 fusion protein with cell transduction proprieties. As previously reported, CDKL5 protein cannot be produced in bacteria due to its massive degradation in prokaryotes (40) . Conversely, we found that production of TATj-CDKL5 in mammalian expression systems is feasible. In order to optimize production yields we created an Igj-TATj-CDKL5 fusion construct. In view of the properties of the Igj-chain leader sequence polypeptide (25) , the TATj-CDKL5 fusion protein produced by the infected cells can be secreted via constitutive secretory pathways. Importantly, due to the transduction properties of the TATj peptide, the secreted TATj-CDKL5 fusion protein is efficiently internalized by target cells. When internalized, the TATj-CDKL5 protein retains the wild-type CDKL5 activity, as demonstrated by its ability to inhibit neuroblastoma cell proliferation (26) and restore maturation of hippocampal neurons that lack CDKL5 expression (14) . It is important to observe that CDKL5, being a high-weight protein, may be liable to undergo conformational modification during the process of purification. Our results show that it is possible to create a fusion protein that retains functional activity even for a high-weight protein like CDKL5, demonstrating that it is possible to overcome the limitations posed by high-weight proteins in the field of protein therapy.
Therapeutic benefits of in vivo protein therapy
CDKL5 KO mice exhibit severe defects in the hippocampal region in terms of dendritic arborization, spine density, and pattern, and show a poorer performance in hippocampusdependent memory and learning tasks compared to wild-type mice (10, (12) (13) (14) . The current study shows that a 10-day intraventricular treatment with TATj-CDKL5 restored maturation of hippocampal neurons in terms of dendritic arbor and spine density. Importantly, hippocampus-dependent behaviors of Cdkl5 KO mice were significantly improved, indicating that the recovery of hippocampal structure in treated Cdkl5 KO mice was functionally effective. Since behavioral testing was carried out during a 10-day period that followed treatment cessation, and assessment of dendritic arborization and spine density were carried out 10 days after treatment cessation, this suggests that the effects of TATj-CDKL5 protein treatment are retained (at least for 10 days) after treatment cessation. Protein treatment with TATj-CDKL5 fusion protein also reduces sleep apnea occurrence and stereotyped behavior (hind-limb clasping) in Cdkl5 KO mice.
Since a therapy based on ICV infusion in human beings is not feasible, we sought to establish whether TATj-CDKL5 protein administered systemically crosses the blood-brain barrier. We found that this was the case and that vascular infusion of TATj-CDKL5 led to restoration of neuroanatomical and behavioral defects in Cdkl5 KO mice. Since visual function is notably impaired in children with CDKL5 disorder and in Cdkl5 KO mice (36, (41) (42) (43) , we examined the effect of systemic treatment on the primary visual cortex (36) . The longitudinal monitoring of the treatment showed that after 10 days of treatment visual responses had recovered in mice treated with TATj-CDKL5 fusion protein, whereas mice treated with control protein had no improvement. Both visual function amelioration and improvement of spine density and PSD-95 puncta staining outlasted the period of treatment, suggesting that discontinuous protocols of treatment could be effective. On the other hand, the restoration of sleep apnea occurrence due to systemic TATj-CDKL5 fusion protein administration did not persist beyond treatment cessation, suggesting that complex behaviors such as sleep breathing require closer or continuous treatments.
Our finding that TATj-CDKL5 is transduced in the brain by both neuronal and glial cells is in line with the nature of the TAT peptide to enter various cell types in a non-selective manner (44) . Although at the moment the CDKL5 function is primarily imputable to its action at the neuronal level, we cannot rule out the possibility that the re-introduction of CDKL5 into non-neuronal cells may partially underlie the behavioral improvement of TATj-CDKL5-treated Cdkl5 KO mice.
Recent studies have shown that various TAT fusion proteins are safe and efficiently transported in vitro and in vivo (45) (46) (47) (48) . A good example is Tat-NR2B9c, an inhibitor of postsynaptic density-95 protein, which has been demonstrated to safely and efficiently reduce ischemic brain damage in cynomolgus macaques and human beings (49, 50) . After 10 days of TATj-CDKL5 protein administration we did not observe evident side effects in terms of body weight or sleep pattern in Cdkl5 KO mice. Assessment of the development of an immune response against therapeutic proteins may represent a critical issue. Regarding this issue, it is important to observe that we found no local inflammatory response after 10 days of treatment, suggesting an absence of immunogenicity problems regarding either the TAT-PTD or the CDKL5 protein. Further investigations are needed in order to establish whether a more prolonged treatment induces side effects.
Taken together, these findings suggest that a TATj-CDKL5 protein therapy (i) is feasible in vivo; (ii) positively impacts on different brain functions and (iii) has no adverse effects.
Conclusions
To date no cure is available for CDKL5 disorder and the standard of care for patients only targets specific symptoms (3).Very recently, pharmacological treatments targeting different signaling pathways were shown to be able to rescue various aspects of brain development in a Cdkl5 KO mouse model (13, 14, 51) . Mutations of CDKL5 are the upstream cause of all the molecular alterations characterizing CDKL5 disorder. Since the only common feature that is certainly shared by all CDKL5 patients is the lack of a functional CDKL5 protein, compensation of this defect with a protein therapy should theoretically restore all the reversible alterations in CDKL5 patients. Protein replacement therapy is commercially available for various lysosomal storage diseases and represents a potentially exciting avenue for other inherited enzyme deficiency disorders that currently lack available treatments (52) (53) (54) (55) . Importantly, several compounds involving PTDs have been tested in humans with no serious adverse effects (56) . To the best of our knowledge, no PTD-tagged proteins have yet entered human clinical trials for brain disorders. Our study demonstrates the feasibility and efficacy of using a TATj-CDKL5 protein as a therapeutic agent in an experimental CDKL5 disease model. It is important to mention that another two lines of Cdkl5 KO mice have been reported (9, 11) . Cdkl5 KO mouse models show a very similar but not always consistent phenotype. Moreover, the deficiency of Cdkl5 in mice does not lead to spontaneous seizures, a common clinical profile in CDKL5 disorder. Therefore, even if our results strongly suggest the potential impact of a TATj-CDKL5 protein therapy for CDKL5 disorder, it remains to be established whether this therapy is equally effective in patients with CDKL5 disorder.
Materials and Methods
Mouse colony
Cdkl5 KO mice were produced and karyotyped as described previously (10) . Cdkl5 À/Y mice and Cdkl5 þ/Y littermate control mice were used for all experiments. The day of birth was designed as postnatal day (P) zero and animals with 24 h of age were considered as one-day-old animals (P1). After weaning, mice were housed 3-5 per cage on a 12 h light/dark cycle in a temperature-(23 C) and humidity-controlled environment with food and water provided ad libitum. The animals' health and comfort were controlled by the veterinary service. Experiments were performed in accordance with the Italian and European Community law for the use of experimental animals and were approved by Bologna University Bioethical Committee. In this study, all efforts were made to minimize animal suffering and to keep the number of animals used to a minimum. (reverse for CDKL5 1 ) and cloned into pPTKGFPXhoI site in frame with upstream GFP sequence and downstream myc sequence. TATj-CDKL5 5 construct was produced as follows: human CDKL5 5 was amplified using the following primers:
CDKL5 vectors
(reverse) and cloned into pPTKGFPAgeI/XhoI sites. TATj-GFP-CDKL5(K42R) 1 construct was performed to generate the inactive kinase K42R through PCR using the following primers: 5'-AAATTCAAGGACAGT GAAGAAAATG-3' (forward); 5'-CCTGATCGCCACAATTTCATG-3' (reverse) and a high fidelity Herculase II Fusion DNA Polymerase (Agilent Technologies, CA, USA). For a detailed diagram of the constructs, see Supplementary Material, Figure S1 .
Stable clones expressing fusion proteins
HEK293T cells were transfected with the following vectors: TATj-GFP, TATj-GFP-CDKL5 5 and TATj-GFP-CDKL5 1 using Lipofectamine 3000 (Invitrogen) transfection reagent according to the manufacturer's instructions. After 3 days, cells were selected with 5 mg/ml puromycin. Selection medium was changed every 3-4 days and clones were picked after 3 weeks. Clones were analyzed for TATj-GFP, TATj-GFP-CDKL5 5 and TATj-GFP-CDKL5 1 expression and successively for protein secretion in culture medium by western blot analysis with an anti-GFP antibody (rabbit polyclonal anti-GFP, 1:1000, Thermo Fisher Scientific) or an anti-CDKL5 antibody (rabbit polyclonal anti-CDKL5, 1:500, Sigma-Aldrich).
Protein purification and concentration
HEK293T cell lines expressing TATj-GFP, TATj-GFP-CDKL5 5 and TATj-GFP-CDKL5 1 were grown for 48 h in serum-free culture medium (Dulbecco's modified Eagle's medium supplemented with 2 mM of glutamine and antibiotics: penicillin, 100 U/ml; streptomycin, 100 lg/ml). The culture medium containing the secreted proteins was collected, centrifuged to pellet cell debris and filtered through 0,2 mm syringe filters. The culture medium was then transferred to Amicon Ultra Centrifugal Filters (Millipore) with 50 kDa molecular weight cut-off, and proteins underwent diafiltration according to the manufacturer 0 s instructions.
Evaluation of protein transduction efficacy
Neuronal cell lines SH-SY5Y neuroblastoma cells were seeded onto poly-D-lysine coated slides in 24-well plates. Twenty-four hours after plating, medium was replaced with fresh DMEM with 10% FBS plus medium containing TATj-GFP-CDKL5 5 protein (50 ng). Thirty minutes after treatment cells were gently washed with PBS 1Â and fixed with a 4% paraformaldehyde solution for 20 min at room temperature and immunocytochemistry with an anti-GFP antibody (rabbit polyclonal anti-GFP, 1:1000, Thermo Fisher Scientific) was performed. Fluorescence images to confirm TATj-GFP-CDKL5 5 localization inside target cells were acquired using a LEICA TCS SL confocal microscope. Images were taken with a 63Â oil immersion objective lens at 0.4 lm intervals (Z-stack).
Primary hippocampal neurons
Primary hippocampal neuronal cultures were prepared from P1 Cdkl5 À/Y and Cdkl5 þ/Y mice as described previously (14) . Protein transduction efficacy was evaluated by western blot analysis on 4-day (DIV4) differentiated hippocampal neurons from Cdkl5 À/Y mice treated for 1 h with concentrated medium containing TATj-GFP-CDKL5 1 protein (50 ng). Cells were gently washed with PBS 1X and directly collected in 2Â SDS-PAGE loading buffer and processed for western blot analysis using an anti-CDKL5 antibody (rabbit polyclonal anti-CDKL5, 1:500, SigmaAldrich). Localization of transduced protein was evaluated on 10-day (DIV10) differentiated hippocampal neurons treated for 1 h either with TATj-GFP or TATj-GFP-CDKL5 1 protein (50 ng).
Immunostaining was performed using the following antibodies: anti-GFP (rabbit polyclonal anti-GFP, 1:1000, Thermo Fisher Scientific), anti-CDKL5 (sheep polyclonal SA145, MRC PPU reagent and service, University of Dundee, UK), anti-synaptophysin [mouse monoclonal anti-SYN (clone SY38) 1:500, Merck Millipore, USA], anti-PSD-95 (mouse monoclonal anti-PSD-95, 1:1000, Abcam, Cambridge, UK), anti-microtubule-associated protein 2 (rabbit polyclonal anti-MAP2, 1:1000, Millipore), anti-glial fibrillary acidic protein (mouse monoclonal anti-GFAP, 1:400, Sigma) and b-tubulin III (rabbit polyclonal anti-TUBJ 1: 100, Sigma). Nuclei were stained either with Hoechst-33342 or TO-PRO-3. Images were acquired using a Nikon Eclipse E600 microscope equipped with a Nikon Digital Camera DXM1200 ATI System (Nikon Instruments Inc., Melville, NY, USA) or a LEICA TCS SL confocal microscope (Leica Microsystems, Wetzlar, Germany). For protein localization images were taken with a 63Â oil immersion objective lens at 1 lm intervals (Z-stack).
Determination of TATj-GFP-CDKL5 1 fusion protein half-life HEK293T cells were treated with concentrated DMEM medium containing TATj-GFP-CDKL5 1 protein (50 ng). At different time points (3, 6, 10 and 24 h) cells were collected in 2X SDS-PAGE loading buffer and processed for western blot analysis using an anti-CDKL5 antibody (rabbit polyclonal anti-CDKL5, 1:500, SigmaAldrich). Densitometric analysis of digitized images was performed using Chemidoc XRS Imaging Systems and Image Lab TM Software (Biorad). The half-life of the TATj-GFP-CDKL5 1 protein was assessed, starting from the densitometric analysis of the protein bands over time. Assuming that protein degradation follows first-order decay kinetics, the logarithm of the fraction of protein that remained over time was plotted versus time. The graph's slope was used to evaluate the degradation rate constant (K). Starting from K, the half-life (t 1/2 ) of the protein, defined as the time required for the protein to halve its quantity, was calculated using the following equation: t 1/2 ¼ ln 2/K (58).
Evaluation of mitotic index
SH-SY5Y cells were treated for 24 h with 50 ng of the listed proteins: TATj-GFP; TATj-GFP-CDKL5 1 or TATj-GFP-CDKL5(K42R) 1 . Cells were fixed with a 4% paraformaldehyde solution for 20 min at room temperature and stained with Hoechst-33342. The mitotic index was evaluated with the number of mitotic cells as a percentage of total cell number for each condition.
Effects of TATj-GFP-CDKL5 1 on Cdkl5 KO hippocampal neurons
For morphological analysis (dendritic length, spine density and synaptic innervation), primary hippocampal neuron cultures from P1 Cdkl5 À/Y and Cdkl5 þ/Y mice were treated with TATj-GFP-CDKL5 1 or TATj-GFP-CDKL5(K42R) 1 protein (50 ng) on alternate days starting from day 2 after plating (DIV2). Cells were fixed at DIV10 and processed for immunofluorescent staining and morphological analysis as described previously (14) . Briefly, dendrite length of microtubule-associated protein 2 (MAP2)-positive neurons was measured and quantified by tracing along each neuronal projection using the image analysis system Image Pro Plus (Media Cybernetics, Silver Spring, MD, USA). The starting point of a dendrite was defined as the point at the midline of the dendrite that intersected the curvature of the soma. For our measures, a protrusion emerging from the cell soma with all its branches was counted as a single dendrite. Fluorescence images to evaluate spine density (MAP2-positive dendritic protrusions) were acquired using a Leica TCS SL confocal 63Â oil immersion lens at 0.6 mm intervals at 1024 Â 1024 pixels resolution with 1Â zoom. The confocal microscope acquisition parameters were kept the same for all scans. Spine density was measured by counting the number of dendritic protrusions (spines) on both primary and secondary dendrites and expressed as the number of spines per 10 mm of dendritic length. The degree of synaptic innervation was evaluated by counting the number of synaptic (SYN) puncta on proximal dendrites and expressed as the number of SYN puncta per mm of dendritic length (14) .
Animal treatments and surgery
Animals were randomly assigned to the different treatments.
Intracerebroventricular cannula implantation and injections
Adult Cdkl5 À/Y mice (4-6 months old) were implanted under general anesthesia (2% isoflurane in pure oxygen) with an ICV guide cannula (diameter 22 G, C313G, Plastics One, USA). The following stereotaxic coordinates were used to place the tip of the cannula in the lateral ventricle: 0.6 mm posterior and 1.2 mm lateral to bregma, 2 mm depth from the bone surface. The cannula was cemented to the skull with dental cement (RelyXUnicem, 3M ESPE, Italy) and dental acrylic (Respal NF, Italy) and plugged with a fitting cap (C313DC Plastics One, USA). Analgesic (Carprofen 5 mg/kg) and antibiotic (12 500 UI/kg benzylpenicillinbenzathine þ 5 mg/kg dihydrostreptomycinsulphate) were given subcutaneously to each mouse. After 7 days of recovery, mice were anesthetized and an internal cannula (diameter 26 G, C312I, Plastics One, USA) connected to a Hamilton syringe was inserted into the guide cannula. Ten microliters of TATj-GFP-CDKL5 1 or TATj-GFP dissolved in saline was injected at a flow rate of 1 ml/min using an infusion pump (Harvard Apparatus, USA; approximately 60 ng/infusion). The treatment period consisted of a single daily injection (10 ll injection, approximately 60 ng/injection) for 5 consecutive days, followed by a two-day rest period and then five additional days of a single injection. Thus, a total of 10 injections were administered over a 12-day period. At the end of treatment, animals were behaviorally tested and sacrificed 10 days after treatment cessation. Mouse body weight was recorded before each injection. The correct cannula position was verified via ink injection (1-2 ml) at sacrifice. For the evaluation of in vivo protein transduction efficiency and localization, ICV injections with TATj-GFP, TATj-GFP-CDKL5 1, TATj-GFP-CDKL5 5 protein (200 ng) or vehicle were performed on adult Cdkl5 À/Y mice (3 months old) as described above and animals were sacrificed 1 or 6 h after a single injection.
Subcutaneous injections
Seven-day-old mouse pups (P7) were subcutaneously injected with TATj-GFP, TATj-GFP-CDKL5 1 , TATj-GFP-CDKL5 5 (200 ng) or vehicle. Animals were sacrificed 4 h after the injection and brains were fixed for immunofluorescent staining.
Intravenous injections
Adult mice Cdkl5 À/Y mice (3 months old) were anesthetized with isoflurane (2% in pure oxygen) and dilation of the tail veins was stimulated by placing the tail in a warmer environment (40 C water bath) for several minutes. TATj-GFP, TATj-GFP-CDKL5 1, TATj-GFP-CDKL5 5 protein preparation (250 ng) or vehicle, in a total volume of 200 ml, was slowly injected into the tail vein. The needle was then removed and an ethanol swab was applied directly to the injection site for 5-10 s to stop any bleeding. Mice were sacrificed 1 h after the injection.
IPRECIO pump implantation and infusions
Catheters for mouse carotid artery (INSTECH Laboratory, USA) were treated with tridodecylmethylammonium chloride (TDMAC, Sigma Aldrich, Italy) and heparin (Vister, 5000 UI/ml, Pfizer) solutions following the manufacturer's instructions to prevent blood clots and then connected to micro infusion refillable pumps (IPRECIO SMP-300, Primetech Corporation, Japan). Adult Cdkl5 À/Y mice (4-6 months old) were anesthetized with isoflurane (2% in pure oxygen), the tip of the catheter was inserted into the internal carotid artery (cranial direction) and the IPRECIO pump was placed subcutaneously on the back of the mouse. Analgesic (Carprofen 5 mg/kg) and antibiotic (12 500 U.I./kg benzylpenicillinbenzathine þ 5 mg/kg dihydrostreptomycinsulphate) were given subcutaneously to each mouse. The IPRECIO reservoir (130 ml) was filled either with TATj-GFP-CDKL5 1 or TATj-GFP, and a 10-day infusion protocol was programmed as followed: 2 daily (1 in the morning and 1 in the evening) boluses (20 ml each corresponding to 50 ng of protein) were administered at 10 ml/h with a low constant release (0.4 ml/h) during the rest of the day to prevent catheter occlusion. Every 2 or 3 days, mice were briefly anesthetized to refill the IPRECIO reservoir (transdermal injection) with fresh solutions. For mice used in the study of hypnic and ventilatory dysfunctions, after 10 days of drug administration (either TATj-GFP-CDKL5 1 or TATj-GFP) the pump reservoir was emptied and refilled with saline. Saline infusions lasted for 10 more days following the same administration protocol. For mice used in the open-field test, after 10 days of drug administration, IPRECIO pumps were removed and the carotid catheter was closed with a fitting cap. New stitches were applied to the backs of the mice and new doses of analgesic and antibiotic were provided. For mice used in the evoked potential study, a long postoperative recovery period (2 weeks) was allowed between the IPRECIO pump implantation and the beginning of drug administration. During this period, each IPRECIO reservoir was filled with saline and just 1 daily bolus (at 10 ml/h for 1 h) was administered with a low constant release (0.6 ml/h) during the rest of the day. The 10-day infusion protocol of drug/vehicle solution was the same used for all the other mice, but it was then followed by 10 more days (washout period) during which saline was continuously administered (at 0.4 ml/h).
Histological and immunohistochemistry procedures
Mice were deeply anesthetized with isoflurane (4% in pure oxygen), brains were removed and cut along the midline and fixed by immersion in 4% paraformaldehyde in 100 mM phosphate buffer, pH 7.4. Brains were stored in fixative for 48 h, kept in 20% sucrose in phosphate buffer for an additional 24 h and then frozen with cold ice. All steps of sectioning, imaging and data analysis were conducted blindly and performed by two different operators.
Brains were cut with a freezing microtome into 30-lm-thick coronal sections that were serially collected. One out of 12 sections from the hippocampal formation were used for immunohistochemistry for doublecortin (goat polyclonal anti-DCX Ab, 1:100, Santa Cruz Biotechnology, Inc.) or anti-PSD-95 (rabbit polyclonal anti-PSD-95 Ab, 1:1000, Abcam, Cambridge, UK) as described previously (12, 14) , or for anti-allograft inflammatory factor 1 (rabbit polyclonal anti-AIF1 Ab, 1:1000, Thermo Fisher Scientific, Inc.). One out of six sections from the visual cortex was used for immunohistochemistry for PSD-95. For brain penetration analyses, brain sections were incubated overnight at 4 C with a primary anti-GFP antibody (rabbit polyclonal anti-GFP, 1:1000, Thermo Fisher Scientific) and for 2 h with an HRP-conjugated anti-rabbit secondary antibody (1:200, Jackson Immunoresearch, West Grove, PE, USA). Detection was performed using the TSA Cyanine 
Golgi staining
Brains were Golgi-stained using the FD Rapid Golgi Stain TM Kit (FD NeuroTechnologies, Inc.) as described previously (59) .
Measurements
Neuron sampling Series of sections across the whole rostro-caudal extent of the DG were used for reconstruction of DCX-positive and Golgi stained neurons. DCX-positive neurons were sampled in the inner part of the granular layer, close to the subgranular zone. The Golgi method casually impregnates a few neurons from among a given population and allows one to sample relatively isolated neurons. Golgi-stained neurons were sampled from the outer part of the granule cell layer and in CA1. The total number of DCX-sampled granule cells was 15-18 per animal and the number of sampled Golgi-stained granule cells and CA1 pyramidal neurons was 10-15 per animal.
Measurement of the dendritic tree
Dendritic trees of DCX-positive granule cells, Golgi-stained granule cells and CA1 pyramidal cells were traced with dedicated software, custom-designed for dendritic reconstruction (Immagini Computer, Milan, Italy), interfaced with Image Pro Plus (Media Cybernetics, Silver Spring, MD, USA). The dendritic tree was traced live, at a final magnification of 500Â, by focusing on the depth of the section. The operator starts with branches emerging from the cell soma and after having drawn the first parent branch goes on with all daughter branches of the next order in a centrifugal direction. At the end of tracing the program reconstructs the total dendritic length, the mean length of branches and the number of segments.
Synaptic terminals
For quantification of PSD-95 immunoreactive synaptic puncta, images from the molecular layer of DG and the primary visual cortex (V1) were evaluated as described previously using a LEICA TCS SL confocal microscope (14) .
Spine density/morphology
In Golgi-stained sections, spines of granule neurons, CA1 pyramidal neurons and pyramidal neurons in layers II/III of the primary visual cortex (V1) were counted using a 100Â oil-immersion objective lens. Dendritic spine density was measured by manually counting the number of dendritic spines and expressed as the number of dendritic spines per 10 lm dendritic length. The number of dendritic segments counted per animal was 10-15.
Behavioral testing
All animal behavioral studies were performed blinded to genotype or treatment. Mice were allowed to habituate to the testing room for at least 1 h before the test, and testing was performed at the same time of the day. The sequence of the tests was arranged to minimize the effect of one test influencing subsequent evaluation of the next test.
Hippocampus-dependent learning and memory behavior Animals were tested in the MWM or the BM, and in the PA task as described previously (14, 60) . For the MWM, a visual cue test was conducted 30 min after the probe test to assess sensorimotor ability and motivation. For this test, the platform was set 1 cm above the water level and marked with a flag so that the mice could locate the platform using a local visual stimulus rather than relying on spatial orientation to extra-maze cues. Animals were excluded from the analysis if they floated in more than 75% of the trials for more than 20 s or failed the visual clue test. For the BM, mice were trained to locate the target hole (with an underneath escape box) from 20 holes (5 cm diameter) evenly spaced around the perimeter of an elevated (60 cm above the floor) circular open field (100 cm diameter) (Ugo Basile, Italy). The escape box was designated as an analog to the hidden platform in the MWM, containing a ramp under the target hole so that mice could enter the escape box easily. Mice were initially placed in the center of the arena covered by a dark cylinder, which was removed 10 s after the start of a trial. All mice were trained with three trials per day for three consecutive days with an inter-trial interval of 30 min. Mice that initially failed to locate the target hole within 3 min were gently guided to the target by the operator. The mouse was left in the escape box for 1 min and then returned to its home cage before the next training trial. On the next day mice were tested for the 'probe trial' (trial duration 90 s) in which the escape box was removed. All training trials and probe trials were videotaped for 3 min and the latency to enter the escape box/target hole were automatically scored by EthoVision10XT software (Noldus, The Netherlands).
Hind-limb clasping
Animals were suspended by their tail for 2 min and hind-limb clasping was assessed independently by two operators from video recordings. A clasping event is defined by the retraction of limbs into the body and toward the midline.
Nesting behavior
Nest-building ability was evaluated as proposed by Deacon (61) . Animals were placed in individual cages with standard bedding and a standard piece of paper towel (23 cm Â 23 cm) was provided 20-24 h prior to evaluation. The nests were assessed independently by two operators using the following scoring system: 0, no nest; 1, primitive flat nest (pad-shaped, consist of a flat paper tissue which slightly elevates a mouse above the bedding); 2, more complex nest (including warping and biting the paper towel); 3, complex accurate cup-shaped nests (with shredded paper interwoven to form the walls of the cup); 4, complex hooded nest, with walls forming a ceiling so the nest becomes a hollow sphere with one opening.
Digging behavior
The test was performed as described previously (61) . Briefly, mice were placed in a clean 36.5 cm Â 20.7 cm Â 14.0 cm cage with approximately 5 cm thick standard wooden bedding. After each test the bedding was flattened, firmed and reused. Test duration was 210 s. The number of digging bouts was recorded. Digging was assessed independently by two operators and defined as coordinated movements of fore-or hind-limbs that displace the substrate.
Open field
To assess locomotion, animals, after removing the pump, were placed in the center of a square arena (50 Â 50 cm) and their behavior was monitored for 20 min using a video camera placed above the center of the arena. Distinct features of locomotor activity, including total distance traveled and average locomotion velocity were scored using EthoVision10XT software (Noldus, The Netherlands). The number of stereotypical jumps (repetitive beam breaks < 1 s) were manually counted by a trained observer who was blind to genotype and treatment. Test chambers were cleaned with 70% ethanol between test subjects.
Non-invasive assessment of sleep and breathing pattern
Hypnic and respiratory phenotypes of Cdkl5 À/Y mice were assessed non-invasively with a validated technique based on WBP (28, 62) . Briefly, each mouse was placed inside a WBP chamber flushed with air at 1.5 l/h for the first 8 h of the light period. The respiratory (WBP chamber pressure) signal was continuously recorded, together with chamber humidity and temperature, digitized, and stored at 128 Hz, 4 Hz and 4 Hz, respectively. The system was calibrated with a 100 ll micro-syringe (Hamilton, Reno, USA) at the end of each recording. The states of wakefulness, non-rapid-eye-movement sleep (NREMS) and rapid-eye-movement sleep (REMS) were blindly scored based on inspection of the raw WBP signal. Quantitative analysis of breathing was restricted to stable sleep episodes ! 12 s because of the frequent occurrence of movement artefacts during wakefulness. Apneas and augmented breaths (sighs) were automatically detected as breaths with T TOT (apneas) or tidal volume (sighs) > 3 times the average T TOT or tidal volume, respectively, for each mouse and sleep state, and detection accuracy was checked on raw recordings. Since we previously demonstrated that the occurrence rate of all sleep apneas is the best biomarker to discriminate Cdkl5 À/Y from control mice (28) , in the present study sleep apneas were not further categorized as post-sigh or spontaneous apneas. WBP recordings were performed both in mice treated with ICV injections and in mice implanted with IPRECIO pumps. For the evaluation of long-term effects of drug treatment, in the latter group of mice WBP recordings were performed after 10 days of drug administration (either with TATj-GFP-CDKL5 1 or TATj-GFP) and were repeated after 5 and 10 more days during which saline was infused.
Assessment of visual responses
The methods employed in (36) were used. Adult Cdkl5 À/Y mice implanted with IPRECIO pumps were box-anesthetized and maintained with isoflurane (respectively, 3% and 1%), placed on a stereotaxic frame, and the head fixed in place using ear bars. Body temperature was controlled using a heating pad and a rectal probe to maintain the animal's body at 37 C. Local anesthesia was provided using subcutaneous lidocaine (2%) injection and eyes were protected with dexamethasone-based ointment (Tobradex, Alcon Novartis). The scalp was removed and the skull carefully cleaned with saline. Skin was secured to the skull using cyanoacrylate. Then a thin layer of cyanoacrylate was poured over the exposed skull to attach a custom-made metal ring (9 mm internal diameter) centered over the binocular visual cortex. When the glue dried, a drop of transparent nail polish was spread over the area to ameliorate optical access. After surgery, the animals were placed in a heated box and monitored to ensure the absence of any sign of discomfort. Before any other experimental procedure, mice were left to recover for at least 36 h. During this period, paracetamol (5 mg/ml) was administered in the water as an analgesic therapy. IOS recordings were performed under isoflurane anaesthesia (0.5-1%) supplemented with an intraperitoneal injection of chlorprothixene hydrochloride (1.25 mg/kg). Images were obtained using an Olympus microscope (BX50WI). Red light illumination was provided by 8 red LEDs (625 nm, Knight Lites KSB1385-1P) attached to the objective (Zeiss Plan-NEOFLUAR 5x, NA: 0.16) using a custom-made metal LED holder. The animal was secured under the objective using a ring-shaped neodynium magnet mounted on an arduino-based 3D printed imaging chamber that also controls eye shutters and a thermostated heating pad (30) . Visual stimuli were generated using Matlab Psychtoolbox and presented on a gamma corrected 9.7 inch monitor, placed 10 cm away from the eyes of the mouse. Contrast reversing Gabor patches (temporal frequency: 4 Hz, duration: 1 s) were presented in the binocular portion of the visual field (À10 to þ10 relative to the horizontal midline and À5 to þ50 relative to the vertical midline) with a spatial frequency of 0.03 cycles per degree, mean luminance 20 cd/m 2 and a contrast of 90%. Visual stimulation was time locked with a 16 bit depth acquisition camera (Hamamatsu digital camera C11440) using a parallel port trigger. Interstimulus time was 14 s. Frames were acquired at 30 fps with a resolution of 512 Â 512 pixels, low-pass filtered with a 2D average spatial filter (30 pixels, 117 lm 2 square kernel), and downsampled to 128 Â 128 pixels. The signal was averaged for at least 120 trials and downsampled to 10 fps. Fluctuations of reflectance (R) for each pixel were computed as the normalized difference from the average baseline (DR/R). For each recording, an image representing the mean evoked response was computed by averaging frames between 0.5 and 2.5 s after stimulation. A region of interest (ROI) was automatically calculated on the mean image of the response, by selecting pixels in the lowest 30% DR/R of the range between the maximal and minimal intensity value. Mean evoked responses were quantitatively measured as the average intensity inside the ROI. To weaken background fluctuations a manually selected polygonal region of reference (ROR) was subtracted. The ROR was placed where no stimulus response, blood vessel artifact or irregularities of the skull were observed (36) .
Statistical analysis
Data from single animals represented the unit of analysis.
Results are presented as mean 6 standard error (SE). Data distribution was assessed using a Kolmogorov-Smirnov nonparametric test of equality. Differences among multiple means were assessed, as indicated, by one-way or repeatedmeasures ANOVAs followed by Fisher's LSD or Holm-Sidak's post-hoc analysis. Datasets with non-parametric distribution were analyzed using the Kruskal-Wallis test. Post hoc multiple comparisons were carried out using Dunn's multiple comparison test. Statistical analyses were performed with GraphPad Prism (version 6.0) or SPSS (version 23). A probability level of P < 0.05 was considered to be statistically significant.
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